This inventor holds 1 USPTO granted patent. Top assignee: Pelemed Co., Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Je Heon Lee and His Patent on Kinase-Inhibiting Indirubin Derivatives.
Introduction
Je Heon Lee is an inventor based in Daejeon, South Korea. His work includes a patent for indirubin derivatives designed to inhibit FLT3 and RET kinases, targets associated with certain diseases, including acute myeloid leukemia.
Latest Patents
Lee is associated with 1 patent: “Indirubin Derivatives Having Heterobicyclic Moieties and the Use Thereof.” The invention concerns novel indirubin compounds with heterobicyclic moieties and their potential use as FLT3 and RET kinase inhibitors. The patent describes the compounds as potentially useful in preventing or treating diseases related to mutant FLT3 and mutant RET, particularly acute myeloid leukemia.
Career Highlights
Lee is associated with Pelemed Co., Ltd. His patent reflects research into compounds that may inhibit kinase activity relevant to disease treatment.
Collaborations
Lee’s listed coworkers include So Deok Lee and Jin Hee Park.
Conclusion
Je Heon Lee’s patent focuses on indirubin-based FLT3 and RET kinase inhibitors, with potential applications in treating diseases such as acute myeloid leukemia.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile